Sanders C C, Sanders W E, Thomson K S
Department of Medical Microbiology, Crieghton University School of Medicine, Omaha, Nebraska 68178, USA.
Eur J Clin Microbiol Infect Dis. 1995;14 Suppl 1:S6-11.
Staphylococci show only marginal susceptibility to the newer fluoroquinolones. Minimum inhibitory concentrations (MICs) for susceptible strains usually range from 0.25 to 2.0 mg/l. As a single mutational event involving the gyrase target or permeability diminishes fluoroquinolone susceptibility fourfold on average, such a mutation in staphylococci would lead to a clinical level of resistance. Therefore, it is not surprising that in some institutions, the use of fluoroquinolones has been quickly followed by greatly increased prevalence of fluoroquinolone-resistant staphylococci. The greatest increase in resistance has been seen among methicillin-resistant staphylococci although increased prevalence of resistance among Staphylococcus saprophyticus and other methicillin-susceptible staphylococci has also been reported. Clinical isolates of staphylococci recovered since the introduction of the fluoroquinolones fall into three fluoroquinolone susceptibility groups: susceptible (MIC < 0.5 mg/l), moderately resistant (MIC 0.5 to 4 mg/l) and highly resistant (MIC > 4 mg/l). The first group represents wild type strains while the second and third groups represent single- and multiple-step mutants, respectively. To prevent increasing prevalence of isolates in the second and third groups, it would be prudent to avoid use of quinolones whenever possible. However, when it is necessary, a fluoroquinolone, which achieves serum/tissue levels eight times the MIC of the infecting strain, should be used.
葡萄球菌对新型氟喹诺酮类药物仅表现出有限的敏感性。敏感菌株的最低抑菌浓度(MIC)通常在0.25至2.0毫克/升之间。由于涉及回旋酶靶点或通透性的单个突变事件平均会使氟喹诺酮类药物的敏感性降低四倍,葡萄球菌中的这种突变会导致临床耐药水平。因此,在一些机构中,氟喹诺酮类药物的使用后很快出现氟喹诺酮耐药葡萄球菌的患病率大幅上升也就不足为奇了。耐药性增加最显著的是耐甲氧西林葡萄球菌,不过也有报道称腐生葡萄球菌和其他甲氧西林敏感葡萄球菌的耐药率也有所上升。自引入氟喹诺酮类药物以来分离出的葡萄球菌临床菌株可分为三个氟喹诺酮敏感性组:敏感(MIC < 0.5毫克/升)、中度耐药(MIC 0.5至4毫克/升)和高度耐药(MIC > 4毫克/升)。第一组代表野生型菌株,而第二组和第三组分别代表单步和多步突变体。为防止第二组和第三组分离株的患病率增加,尽可能避免使用喹诺酮类药物是明智的。然而,如有必要,应使用一种能使血清/组织水平达到感染菌株MIC八倍的氟喹诺酮类药物。